Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
| Group | Value (kilocalories per day (kcal/day)) | Spread |
|---|---|---|
| Placebo | -154.36 | 19.69 |
| 15 mg Tirzepatide | -134.68 | 21.62 |
Trial · Interventional
CompletedPhase 1Results postedRegistry dataUnited States
1 trial · 1 completed · 1 with posted results
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
NCT040813379 Jul 2020 to 26 May 2022
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
Placebo comparator
Placebo
Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
Experimental
15 Milligram (mg) Tirzepatide
Participants received 15 mg of tirzepatide QW by SC injection.
Outcomes the sponsor listed as primary.
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
Time frame · Baseline, Week 18
SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal
Time frame · Baseline, Week 18
Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
Time frame · Baseline, Week 18
24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
Time frame · Baseline, Week 18
Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 \[Liter/24hour\] / total VO2 \[Liter/24hour\]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Sleep RQ
Time frame · Baseline, Week 18
Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Duration of Periods With RQ<0.80
Time frame · Baseline, Week 18
RQ\<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ \<0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Time frame · Baseline, Week 18
Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented. * Protein Oxidation = 6.25\*\[urinary nitrogen\] * Fat Oxidation = 1.689\*\[total oxygen consumption (VO2)\] - 1.689\*\[total carbon dioxide production (VCO2)\] - 0.324\*\[protein oxidation\] * Carbohydrate Oxidation = 4.113\*\[VCO2\] - 2.907\*\[VO2\] - 0.375\*\[protein oxidation\]. Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Body Weight (BW)
Time frame · Baseline, Week 18
Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.
Change From Baseline to Week 18 in Body Fat-Free Mass
Time frame · Baseline, Week 18
Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Body Fat Mass
Time frame · Baseline, Week 18
Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Percentage of Body Fat Mass
Time frame · Baseline, Week 18
The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Lipid Metabolism Parameters
Time frame · Baseline, Week 18
Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Fasting Insulin Resistance
Time frame · Baseline, Week 18 during standardized mixed meal tolerance test
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= \[Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)\] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity
Time frame · Baseline, Week 18
Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of \<2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT
Time frame · Baseline, Week 18
Total AUC from time zero to 4 hours after start of the meal \[AUC0-4 hours\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)
Time frame · Baseline, Week 18
HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (kilocalories per day (kcal/day)) | Spread |
|---|---|---|
| Placebo | -154.36 | 19.69 |
| 15 mg Tirzepatide | -134.68 | 21.62 |
| Group | Value (kilocalories (kcal)) | Spread |
|---|---|---|
| Placebo | -58.57 | 82.29 |
| 15 mg Tirzepatide | -914.51 | 82.29 |
| Group | Value (kcal/day) | Spread |
|---|---|---|
| Placebo | -296.85 | 27.67 |
| 15 mg Tirzepatide | -300.07 | 30.44 |
| Group | Value (Ratio) | Spread |
|---|---|---|
| Placebo | 0.005 | 0.005 |
| 15 mg Tirzepatide | -0.030 | 0.006 |
| Group | Value (ratio) | Spread |
|---|---|---|
| Placebo | -0.001 | 0.006 |
| 15 mg Tirzepatide | -0,028 | 0.006 |
| Group | Value (minute) | Spread |
|---|---|---|
| Placebo | 2.55 | 43.97 |
| 15 mg Tirzepatide | 254.44 | 47.14 |
| Group | Value (gram/day) | Spread |
|---|---|---|
| Placebo | -0.14 | 1.23 |
| 15 mg Tirzepatide | -7.00 | 1.32 |
| Group | Value (kilogram (kg)) | Spread |
|---|---|---|
| Placebo | -8.26 | 0.90 |
| 15 mg Tirzepatide | -16.73 | 0.92 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| PlaceboParticipants received placebo once weekly by SC injection. | 0 / 28 | 0 / 28 | 19 / 28 |
| 15 mg TirzepatideParticipants received 15 mg of tirzepatide once weekly by subcutaneous injection. | 0 / 27 | 1 / 27 | 22 / 27 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
No study cites this trial.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated